

REVIEW

miR-21, a potential therapeutic target of alleviating blood-brain barrier damage after traumatic brain injury

Xintong Ge^{1,2,3}, Ping Lei^{4,5}, Jianning Zhang^{1,2,3}¹Key Laboratory of Post-trauma Neuro-repair and Regeneration in Central Nervous System, Ministry of Education, Tianjin 300052, China; Tianjin Key Laboratory of Injuries, Variations and Regeneration of Nervous System, Tianjin 300052, China²Laboratory of Neuro-Trauma, Tianjin Neurological Institute, Tianjin 300052, China³Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, China⁴Department of Geriatrics, Tianjin Medical University General Hospital, Tianjin 300052, China⁵Laboratory of Neuro-Trauma and Neurodegenerative Disorders, Tianjin Geriatrics Institute, Tianjin 300052, China

Correspondence: Ping Lei or Jianning Zhang

E-mail: leiping1974@163.com or jianningzhang@hotmail.com

Received: February 25, 2015

Published: October 23, 2015

Traumatic brain injury (TBI) is a disease with high morbidity and leads to high rate of disability and mortality. The blood-brain barrier (BBB) damage is an important pathological change in brain after TBI, which impacts the development and prognosis of the disease. In our previous research, we have reported that miR-21-5p in neurons can exert an anti-apoptosis effect, and promote the restoration of injured BBB after TBI. Up-regulation of miR-21-5p level in brain can amplify the above functions of miR-21-5p, thus alleviate BBB damage and improve the neurological prognosis of TBI. miR-21-3p, which is generated from pre-miR-21 at the same time with miR-21-5p, has been reported to play significant roles in regulating cellular apoptosis, immuno-inflammatory responses and the expression of angiogenic factors in various diseases. We made a summary of previous research on miR-21-3p and inferred that miR-21-3p could exert an important impact on BBB damage after TBI. Taken together, miR-21 is a vital miRNA that impacts the restoration of injured BBB, thus it could be a potential therapeutic target for interventions in TBI.

Keywords: traumatic brain injury; miR-21; blood-brain barrier**To cite this article:** Xintong Ge, et al. miR-21, a potential therapeutic target of alleviating blood-brain barrier damage after traumatic brain injury. RNA Dis 2015; 2: e642. doi: 10.14800/rd.642.

Traumatic brain injury (TBI) is the leading cause of long-term disability in children and young adults. About 10 million people are affected by a new TBI event every year around the world^[1]. With the development of urbanization, the increase of traffic accidents and regional wars, the incidence of TBI is increasing rapidly in recent years^[2]. Scientists predict that TBI will be the third largest cause of worldwide disease by 2020^[3].

Elucidating the pathological changes involved in TBI and improving the clinical treatment level for TBI has long been important issues for neuroscientists and neurosurgeons. The

primary insult leads to not only primary brain damage (including cerebral contusion and laceration, extradural hematoma, subdural hematoma, intracranial hemorrhage, subarachnoid hemorrhage, etc.), but also a series of pathological events like immuno-inflammatory responses and cellular apoptosis/necrosis in brain^[4]. These pathological events interact with each other and develop concurrently. They result in secondary brain damage, which mainly includes nerve cells apoptosis, impaired local blood supply and BBB damage^[5]. The BBB damage is an important pathological change in brain that it is a significant cause of

serious complications of TBI, like brain edema, intracranial infection and subsequent neurological dysfunction^[6]. As the primary insult cannot be therapeutically influenced, promoting the restoration of injured BBB is crucial for treating and improving the prognosis of TBI.

The clinical therapeutic methods for TBI mainly includes oxygen inhalation therapy, decompressive craniectomy, evacuation of intracranial hematoma, dehydrant and neurotrophic drug treatment. As these methods are not aimed at directly alleviating BBB damage, their therapeutic effects are limited in controlling secondary brain damage. The high-dose glucocorticoid pulse therapy was supposed to be effective in alleviating BBB damage after TBI. However, a clinical trail (MRC CRSAH) involved 10008 patients conducted in more than 40 countries demonstrated that corticosteroids does not have any therapeutic effect on TBI patients in spite of the time of administration post-injury^[7]. Our previous research also proved that high-dose methylprednisolone can aggravate cellular apoptosis and BBB damage in hypothalamus, which can exacerbate the acute critical illness-related corticosteroid insufficiency associated with TBI^[8-9]. Molecular therapy for TBI has become the research hotspot in recent years. The function of erythropoietin, progesterone and other molecules in alleviating BBB damage have been widely confirmed in animal models. However, these therapeutic methods are not effective in TBI patients according to the reports of clinical trials^[10, 11]. Therefore, exploring new therapeutic strategies for alleviating BBB damage is crucial for the clinical treatment of TBI.

miR-21 is a non-protein coding RNA molecule that negatively modulate the expression of its target proteins. It has been proved to be an oncogene and implicated in the etiology of a variety of diseases, like cancer and cardiovascular diseases. However, little attention has been paid to their roles in acute diseases, such as TBI. Mature miR-21 includes miR-21-5p and miR-21-3p. They are both generated from pre-miR-21 at the same time through several steps of enzyme digestion^[12]. As to the previous research on miR-21-5p, Redell^[13] and our group^[14] have detected the miRNAs change in brain of TBI rats using miRNAs profiling and qRT-PCR, indicating that the expression level of miR-21-5p in the hippocampus and injured cerebral cortex were both increased from 6 h to 72 h post-injury. PDCD4 and Tiam1 were predicted to be the target genes of miR-21-5p after TBI^[14]. These findings suggest that miR-21-5p is a potential biomarker and therapeutic target in TBI. In addition, Sandhir^[16] found that miR-21-5p showed no increased expression in response to injury in aging mice following TBI, and the expression of its target genes, including PTEN and PDCD4, were up-regulated. As the activation of PTEN and

PDCD4 can promote cellular apoptosis, the diminished miR-21-5p injury response may contribute to the poor prognosis of aged mice compared to the adult. Consequently, strategies aimed at up-regulation of miR-21-5p and/or down regulation of its targets might be useful in improving outcomes following TBI.

Since 2009, we has performed a series of research on the function and mechanism of miR-21 in TBI. We have proved that neurons-expressed miR-21-5p exerted an anti-apoptosis effect in brain after TBI, thereby promoting the restoration of injured BBB and improving the neurological prognosis of TBI^[15, 17-19]. Specifically, we employed the fluid percussion injury rat model, and detected the expression level of miR-21-5p in the traumatic foci using qRT-PCR. We found that the miR-21-5p level was increased from 6 h to 72 h post-injury, and it can be further up-regulated or down-regulated by intracerebroventricularly injection of miR-21-5p agomir or antagomir^[18]. We then measured the expression of miR-21-5p in neurons, astrocytes, microglias and brain microvascular endothelial cells (BMVECs) respectively using combined miRNA in-situ hybridization and immunofluorescence. We found that compared to astrocytes and microglias, neurons and BMVECs expressed more miR-21-5p, and their miR-21-5p levels are more sensitive in response to injury^[18]. We evaluated the influence of miR-21-5p on the neurological outcome of TBI rats using modified neurological severity score and Morris Water Maze. We found that the increased miR-21-5p level in brain post-injury was beneficial for improving the neurological prognosis of TBI^[18]. Then, we observed the impact of miR-21-5p on cellular apoptosis in rats and in-vitro cultured neurons to investigate the mechanism of its protective effect in TBI. We confirmed that miR-21 inhibited apoptosis in neurons through inhibiting PTEN expression at the post-transcriptional level and activating Akt signaling^[18-19]. In addition, we evaluated the impact of miR-21-5p on BBB damage by measuring brain water content, the amount of Evan's Blue extravasation and the expression level of tight junction proteins in brain. We demonstrated that miR-21-5p can alleviate BBB damage by activating Ang-1/Tie-2 axis. And this effect is also associated with its inhibition on cellular apoptosis in brain^[17-18]. Taken together, up-regulation of miR-21-5p level in brain can inhibit the cellular apoptosis and alleviate BBB damage, thus improve the neurological prognosis of TBI.

Recently, the biological function of miRNA* in various diseases began to drawn increasing attention from scientists. As to miR-21-3p (miR-21*), it has been confirmed that its expression is significantly up-regulated in various tumor cells, including non-small cell lung cancer^[20], colorectal cancer^[21] and several human carcinomas^[22]. Besides,

miR-21-3p can activate the Akt signaling that regulates cellular apoptosis in breast tumors^[23]. The research on human aortic endothelial cells also found that miR-21-3p is an up-stream regulator of NF- κ B signaling that can regulate the immuno-inflammatory responses^[24]. In the research on cardiac hypertrophy, miR-21-3p has been proved to have the function of impacting the hypertrophic progress of cardiomyocytes induced by Ang-2 infusion, suggesting that miR-21-3p could regulate the expression of angiogenic factors, such as Ang-1 and Ang-2^[25-26]. Taken together, miR-21-3p may possibly have the function of regulating cellular apoptosis, immuno-inflammatory responses and the expression of angiogenic factors in brain. From this, we inferred that miR-21-3p could exert an important impact on BBB damage after TBI. And we have planned to study the function and mechanism of miR-21-3p in regulating the restoration of BBB damage in the future.

In conclusion, miR-21 is a vital miRNA that impacts the restoration of injured BBB, thus it could be a potential therapeutic target for interventions in TBI. The outcome of our work has further elucidated the mechanism of BBB damage and restoration, and also provided insights into developing a novel therapeutic strategy for TBI.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (grant no. 81330029, 81471252 and 81271361), Tianjin Municipal Science and Technology Commission natural fund project (grant no. 13JCYBJC23700) and National Clinical Key Subject Construction Project of NHFPC Fund. We also express special acknowledgement to the senior professor Chunsheng Kang who contributes greatly on this work.

References

1. Feigin VL, Theadom A, Barker-Collo S, Starkey NJ, McPherson K, Kahan M, *et al.* Incidence of traumatic brain injury in New Zealand: a population-based study. *Lancet Neurol* 2013; 12: 53-64.
2. Cope EC, Morris DR and Levenson CW. Improving treatments and outcomes: an emerging role for zinc in traumatic brain injury. *Nutr Rev* 2012; 70: 410-413.
3. Traumatic brain injury: time to end the silence. *Lancet Neurol* 2010; 9: 331.
4. Blennow K, Hardy J and Zetterberg H. The neuropathology and neurobiology of traumatic brain injury. *Neuron* 2012; 76: 886-899.
5. Khan M, Im YB, Shunmugavel A, Gilg AG, Dhindsa RK, Singh AK, *et al.* Administration of S-nitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled cortical impact. *J Neuroinflammation* 2009; 6: 32.
6. Zweckberger K, Eros C, Zimmermann R, Kim SW, Engel D and Plesnila N. Effect of early and delayed decompressive craniectomy on secondary brain damage after controlled cortical impact in mice. *J Neurotrauma* 2006; 23: 1083-1093.
7. Edwards P, Arango M, Balica L, Cottingham R, El-Sayed H, Farrell B, *et al.* Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. *Lancet* 2005; 365: 1957-1959.
8. Chen X, Zhao Z, Chai Y, Luo L, Jiang R, Dong J, *et al.* Stress-dose hydrocortisone reduces critical illness-related corticosteroid insufficiency associated with severe traumatic brain injury in rats. *Crit Care* 2013; 17: R241.
9. Chen X, Zhang B, Chai Y, Dong B, Lei P, Jiang R, *et al.* Methylprednisolone exacerbates acute critical illness-related corticosteroid insufficiency associated with traumatic brain injury in rats. *Brain Res* 2011; 1382: 298-307.
10. Skolnick BE, Maas AI, Narayan RK, van der Hoop RG, MacAllister T, Ward JD, *et al.* A clinical trial of progesterone for severe traumatic brain injury. *N Engl J Med* 2014; 371: 2467-2476.
11. Robertson CS, Hannay HJ, Yamal JM, Gopinath S, Goodman JC, Tilley BC, *et al.* Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. *JAMA* 2014; 312: 36-47.
12. Okamura K, Phillips MD, Tyler DM, Duan H, Chou YT and Lai EC. The regulatory activity of microRNA* species has substantial influence on microRNA and 3' UTR evolution. *Nat Struct Mol Biol* 2008; 15: 354-363.
13. Redell JB, Liu Y and Dash PK. Traumatic brain injury alters expression of hippocampal microRNAs: potential regulators of multiple pathophysiological processes. *J Neurosci Res* 2009; 87: 1435-1448.
14. Lei P, Li Y, Chen X, Yang S and Zhang J. Microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury. *Brain Res* 2009; 1284: 191-201.
15. Redell JB, Zhao J and Dash PK. Altered expression of miRNA-21 and its targets in the hippocampus after traumatic brain injury. *J Neurosci Res* 2011; 89: 212-221.
16. Sandhir R, Gregory E and Berman NE. Differential response of miRNA-21 and its targets after traumatic brain injury in aging mice. *Neurochem Int* 2014; 78: 117-121.
17. Ge X, Han Z, Chen F, Wang H, Zhang B, Jiang R, *et al.* miR-21 alleviates secondary blood-brain barrier damage after traumatic brain injury in rats. *Brain Res* 2015.
18. Ge XT, Lei P, Wang HC, Zhang AL, Han ZL, Chen X, *et al.* miR-21 improves the neurological outcome after traumatic brain injury in rats. *Sci Rep* 2014; 4: 6718.
19. Han Z, Chen F, Ge X, Tan J, Lei P and Zhang J. miR-21 alleviated apoptosis of cortical neurons through promoting PTEN-Akt signaling pathway in vitro after experimental traumatic brain injury. *Brain Res* 2014; 1582: 12-20.
20. Jiang M, Zhang P, Hu G, Xiao Z, Xu F, Zhong T, *et al.* Relative

- expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients. *Mol Cell Biochem* 2013; 383: 67-75.
21. Wu D, Tang R, Qi Q, Zhou X, Zhou H, Mao Y, *et al.* Five functional polymorphisms of B7/CD28 co-signaling molecules alter susceptibility to colorectal cancer. *Cell Immunol* 2014; 293: 41-48.
 22. Doberstein K, Bretz NP, Schirmer U, Fiegl H, Blaheta R, Breunig C, *et al.* miR-21-3p is a positive regulator of LICAM in several human carcinomas. *Cancer Lett* 2014; 354: 455-466.
 23. Aure MR, Leivonen SK, Fleischer T, Zhu Q, Overgaard J, Alsner J, *et al.* Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors. *Genome Biol* 2013; 14: R126.
 24. Romay MC, Che N, Becker SN, Pouldar D, Hagopian R, Xiao X, *et al.* Regulation of NF-kappaB signaling by oxidized glycerophospholipid and IL-1beta induced miRs-21-3p and -27a-5p in human aortic endothelial cells. *J Lipid Res* 2015; 56: 38-50.
 25. Bang C, Batkai S, Dangwal S, Gupta SK, Foinquinos A, Holzmann A, *et al.* Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. *J Clin Invest* 2014; 124: 2136-2146.
 26. Yan M, Chen C, Gong W, Yin Z, Zhou L, Chaugai S, *et al.* miR-21-3p regulates cardiac hypertrophic response by targeting histone deacetylase-8. *Cardiovasc Res* 2014.